Indivior Pharmaceuticals, Inc. (INDV) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
the bull case· 3
73.00%
share of Aquestive Therapeutics revenue coming from the company in their filing
10-Kfrom their filing335
managers reporting a position in thirteen f filings
13fJun 30 '26+1.90%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 4
13 of 23
thirteen of twenty three largest reporting managers cut stakes in the latest quarter
13fJun 30 '263
funds on file reporting a position in the company
n-portas of Jun 30 '260.15%
share of iShares Russell two thousand ETF assets as largest fund weight
n-portJun 30 '2635
thirty five managers whose positions comprise four fifths of reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Feb 25 '27 report. Not a forecast, not advice.
High 35.83 at 4:00 am ET, low 34.65 at 11:45 am ET.
Of the 6 companies Indivior Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 158 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
334 managers report a position worth $5.1B between them, and 35 of them hold 80% of it.
INDV (Indivior Pharmaceuticals, Inc.) has 5 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record